Brief: Ampio To Start First Clinical Trial In COVID-19 Program
19/06/2020 13:15
June 19 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO TO START FIRST CLINICAL TRIAL IN COVID-19 PROGRAM
* AMPIO PHARMACEUTICALS - WILL BEGIN PHASE 1 CLINICAL TRIAL
TO
EVALUATE IV AMPION AS A TREATMENT FOR COVID-19 PATIENTS ON
SUPPLEMENTAL OXYGEN
Source text for Eikon: ID:nPn85XyRla
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank